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Summary: Drug development follows a very specific path, from 
preclinical safety and quality ascertainment to clinical development 
to market authorization and postmarketing surveillance. The whole 
process is geared to the pharmaceutical industry, which indeed has 
all the know-how and experience to bring a drug to market, espe-
cially when it is also the originator of the future drug. When the 
product is derived from academic research, can academia initiate 
drug development, and at what stages? This will depend on the 
availability of the appropriate resources in the academic and/or 
private sectors, and the funding for these. Preclinical drug devel-
opment is not overly expensive, especially for the basic elements 
needed to pursue drug development and to bring the drug to clini-
cal testing. If the quality issues can be controlled (drug synthesis, 
stability testing), basic toxicity testing can be outsourced to any 
of many specialized companies. Obviously, academic laboratories 
should have all the required resources for pharmacodynamic testing 
and demonstration. Clinical trials can be done in the appropriate 
clinical investigation centers, and the academic hospitals of course 
have all the patients needed for the clinical trials, because this is 
usually where industry actually does them. Therefore, academia 
(including public hospitals and research centers) has all the required 
knowledge and resources needed to develop a drug and bring it to 
market. What may be most lacking at the premarket phase is financ-
ing, and finding this is not easy, especially at the later-phase clinical 
trials, which are usually multicenter and require heavy logistical 
resources. Recently developed networks and structures (E-CRIN, 
F-CRIN) aim to help these large multicenter studies. Increasing 
awareness by the public research-financing bodies of the need to be 
able to develop alternatives to industrial development, especially for 
certain types of drugs (drugs for rare diseases or new uses for old 
drugs), may also increase the involvement of academia in de novo 
drug development. Of course, public–private partnerships should 
continue, both through involvement of industry expertise during 
academia-initiated development and through the increasingly evi-
dent involvement of academia during later-phase clinical develop-
ment of major new drugs, if only to avoid unnecessary suspicions of 
industrial misconduct, much as is done in the postmarketing arena 
with the ENCEPP code of conduct.
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Summary: Transporters are membrane proteins, which medi-
ate the translocation of chemicals into and out of cells. The past 
10 years have seen an enormous increase in research concerning 
the role of membrane transporters in drug pharmacokinetics and 
response.1 In particular, influx and efflux transporters expressed 
on the plasma membranes of polarized cells in tissues important 
for pharmacokinetics have the potential to significantly affect 
drug response. Certain transporters have been shown to mediate 
clinically important drug interactions. For example, the immuno-
suppressive drug cyclosporine increases the systemic exposure to 
all statins, by ~5- to 20-fold, probably mainly by inhibiting their 
organic anion transporting polypeptide (OATP)-mediated hepatic 
uptake.3 Similarly, cyclosporine raises the systemic exposure to 
the OATP1B1 substrate antidiabetic repaglinide by 2.5-fold.2 
Furthermore, the P-glycoprotein efflux transporter-inhibiting anti-
mycotic itraconazole raises the systemic exposure to the antihy-
pertensive aliskiren on average 6.5-fold.4 These and other roles of 
OATPs, P-glycoprotein. and other membrane transporters in drug 
interactions will be discussed.
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Summary: Twenty years ago, there were almost no pharmacovigi-
lance (PV) activities in low-and middle-income countries (LMIC). 
Today, 144 countries are participating in the WHO Programme 
for International Drug Monitoring, and 102 of them belong to the 
LMIC category according to the World Bank classification. Many 
factors have contributed to the positive development. Among them 
are:
-  Creation of evidence of the general burden of drug-related harm 
in all populations
-  Concerns of the high prevalence of substandard and fake medicines 
in LMIC
-  Capacity building and competence development in PV, mainly 
driven by the WHO Programme
-  Public health programs realizing that drug-related harm may jeop-
ardize program success
-  Global health initiatives and donor organizations prepared to 
protect public health programs also by supporting pharmacovigi-
lance
Most of the national pharmacovigilance systems in LMIC still 
have inadequate capacity to adequately protect their populations 
from the risk of medicine and medicine use–related harm. There are 
many challenges that need to be addressed; for example:
-  The capacity of National Regulatory Authorities and collaboration 
and integration with vertical disease programs
-  Training of health workers, local industry, and the public about the 
need to record and report medicine-related harm
- Keeping of systematic patient records
-  Documentation of the burden of medicine-related harm in the local 
setting
In most LMICs, the first requisite for PV activities, the politi-
cal will, is in place. Further support for the young PV systems is 
needed to make them fully functional. The WHO Programme builds 
regional and global networks to support PV in LMIC particularly 
